Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Sarah Mount: Pregnancy, Hypercoagulability, and Erythritol
Sarah Mount/LinkedIn
Feb 19, 2026, 13:36

Sarah Mount: Pregnancy, Hypercoagulability, and Erythritol

Sarah Mount, Postdoctoral Researcher at Maastricht University, shared on LinkedIn:

”Pregnancy, Hypercoagulability, and Erythritol — A Conversation We Should Be Having

Pregnancy is not a neutral physiological state when it comes to clotting.

It is a well-established hypercoagulable condition, designed to protect against haemorrhage — but one that increases the risk of thrombosis.

That baseline risk is compounded by:

  • Gestational diabetes
  • Hypertensive disorders of pregnancy (including pre-eclampsia)
  • Chronic hypertension
  • Obesity and metabolic dysfunction
  • Inherited thrombophilia’s ex. Factor V Leiden (often undiagnosed, as universal screening is not routine).

Placental function depends on stable microvascular blood flow. When thrombotic risk rises, placental complications — including abruption and infarction — can escalate rapidly.

Now consider emerging data on erythritol (E968).

A 2023 study published in Nature Medicine reported that higher circulating erythritol levels were associated with increased risk of major adverse cardiovascular events (MI, stroke, death) over three years in high-risk populations.

Experimental components of the study demonstrated enhanced platelet activation and thrombosis formation in vitro and in animal models.

A subsequent human intervention study showed that ingestion of erythritol-sweetened beverages can produce plasma levels associated with these pro-thrombotic effects.

Moreover, there are more recent studies examining erythritol and blood-brain barrier integrity, as well as cardiovascular event risks.

Importantly:
These studies show association and mechanistic plausibility — not proven causation.

Erythritol remains ‘generally recognised as safe’ under current regulatory frameworks. Pregnancy-specific outcome data are lacking.

But here is the clinical question:

In a population already in a hypercoagulable state — sometimes with additional metabolic, hypertensive, or genetic risk factors — does it seem unreasonable to at least discuss minimising exposure to compounds with emerging pro-thrombotic signals?

This is not alarmism. It is risk stratification.

At minimum, this appears to be a reasonable topic for informed discussion between pregnant patients and their obstetric providers.

And then there is labelling…”

Stay updated with Hemostasis Today.

erythritol Health Hematology Hemostasis Hemostasis News Hemostasis Today Hypercoagulability hypertension Medicine Obesity Pregnancy Sarah Mount thrombosis
NewsFeed